Chris Raymond
Analyst
Raymond James
Equibles does not estimate personal net worth.
About Chris Raymond
Chris Raymond is recorded as Analyst at Raymond James. Chris Raymond has spoken on 10 earnings calls and 2 other investor events across 5 companies, most recently for Sionna Therapeutics, Inc. on September 14, 2026. Those appearances were for Biomarin Pharmaceutical Inc (BMRN), Taysha Gene Therapies, Inc. (TSHA), Sionna Therapeutics, Inc. (SION), Ardelyx, Inc. (ARDX) and Regeneron Pharmaceuticals, Inc. (REGN). The companies whose calls Chris Raymond spoke on are classified in the Healthcare sector.
Chris Raymond on recent calls
“Have you seen any individual responses to the add-on therapy that met that 10-millimole per liter bar for success? Did anyone in the placebo group, I guess, hit that bar as well?”
“And I'm really sorry also to see this data. Just a couple questions, I guess. Have you seen any individual responses to the add-on therapy that met that 10 millimole per liter bar for success?”
“You guys have had pretty active business development efforts for a bit of time now. Can you talk about your view on the current environment for finding assets and opportunities in light of all the recent M&A activity going on in the industry?”
“First, on Amicus, you guys gave a lot of metrics here on synergies with this integration. Just looking at 2028 synergies that look really impressive.”
“Just on cash management, so you guys have about $18 billion on hand now with the Sanofi obligations sort of rolling off. I guess it seems that that will be accelerating pretty meaningfully.”
Affiliation history
-
Raymond James
Analyst
Transcript header (unverified)
Current
Company network
Ardelyx, Inc.
ARDX
Biotechnology · Healthcare
2 appearances
Latest appearance 2026-08-06
View calls and events